[A20-79] Secukinumab (non-radiographic axial spondyloarthritis) - Benefit assessment according to §35a Social Code Book V
Last updated 01.12.2020
Project no.:
A20-79
Commission:
Commission awarded on 28.08.2020 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Muscles, bones and joints
Indication:
| Adults with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation who have responded inadequately to NSAIDs |
Result of dossier assessment:
| Added benefit not proven due to a lack of study data |
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.